Vincerx Pharma, Inc. (VINC) — SEC Filings
Vincerx Pharma, Inc. (VINC) — 44 SEC filings. Latest: DEFA14A (Jul 16, 2025). Includes 20 8-K, 6 SC 13G/A, 5 DEFA14A.
View Vincerx Pharma, Inc. on SEC EDGAR
Overview
Vincerx Pharma, Inc. (VINC) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEFA14A filed on Jul 16, 2025: Vincerx Pharma, Inc. filed a Definitive Additional Materials proxy statement on July 16, 2025. This filing relates to the company's proxy materials, indicating it's providing supplementary information to shareholders. The company, formerly known as LifeSci Acquisition Corp. and Vincera Pharma, Inc.,
Sentiment Summary
Across 44 filings, the sentiment breakdown is: 3 bearish, 41 neutral. The dominant filing sentiment for Vincerx Pharma, Inc. is neutral.
Filing Type Overview
Vincerx Pharma, Inc. (VINC) has filed 5 DEFA14A, 20 8-K, 4 10-Q, 4 DEF 14A, 2 10-K, 3 SC 13G, 6 SC 13G/A with the SEC between Jan 2024 to Jul 2025.
Filings by Year
Recent SEC Filings (44)
Risk Profile
Risk Assessment: Of VINC's 34 recent filings, 3 were flagged as high-risk, 17 as medium-risk, and 14 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Key Executives
- Dr. Michael R. Bristow
- Dr. David J. Bear
- Dr. Michael J. Ybarra
- Dr. Ahmed M. M. El-Masry
- Ahmed M. Hamdy
Industry Context
Vincerx Pharma operates in the pharmaceutical preparations industry, focusing on the development of novel therapeutics.
Top Tags
corporate-governance (6) · filing (4) · 10-Q (4) · proxy-statement (4) · proxy-filing (3) · agreement-termination (3) · delisting (3) · listing-standards (3) · corporate-action (3) · material-agreement (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Reporting Period End Date | 2025-03-31 | This is the end date for the financial reporting period covered by the 10-Q. |
| Previous Year End Date | 2024-12-31 | Provides a comparison point for financial performance. |
| Prior Year Q1 End Date | 2024-03-31 | Allows for year-over-year quarterly comparison. |
| Reverse Stock Split | 1-for-20 | Effected in January 2025, impacting all share data. |
| Fiscal Year End | 2024-12-31 | The period covered by the 10-K filing. |
| Filing Date | 2025-03-27 | The date the 10-K was submitted to the SEC. |
| SEC File Number | 001-39244 | Identifies the company's filing with the SEC |
| IRS Employer Identification No. | 83-3197402 | Company's tax identification number |
| Prior Year Quarter End Date | 2023-03-31 | End date of the comparable prior year quarter |
| Name Change Date | 2020-12-23 | Date of name change from Vincera Pharma, Inc. |
| Annual Meeting Date | May 23, 2024 | 2024 Annual Meeting of Stockholders. |
| Annual Meeting Time | 10:00 a.m. Pacific Time | 2024 Annual Meeting of Stockholders. |
| Directors to be Elected | 3 | Number of Class I directors to be elected. |
| Director Term End | 2027 | Term for which Class I directors will serve. |
| Prior Fiscal Year End | 2022-12-31 | Comparative financial data |
Frequently Asked Questions
What are the latest SEC filings for Vincerx Pharma, Inc. (VINC)?
Vincerx Pharma, Inc. has 44 recent SEC filings from Jan 2024 to Jul 2025, including 20 8-K, 6 SC 13G/A, 5 DEFA14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of VINC filings?
Across 44 filings, the sentiment breakdown is: 3 bearish, 41 neutral. The dominant sentiment is neutral.
Where can I find Vincerx Pharma, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Vincerx Pharma, Inc. (VINC) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Vincerx Pharma, Inc.?
Key financial highlights from Vincerx Pharma, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for VINC?
The investment thesis for VINC includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Vincerx Pharma, Inc.?
Key executives identified across Vincerx Pharma, Inc.'s filings include Dr. Michael R. Bristow, Dr. David J. Bear, Dr. Michael J. Ybarra, Dr. Ahmed M. M. El-Masry, Ahmed M. Hamdy.
What are the main risk factors for Vincerx Pharma, Inc. stock?
Of VINC's 34 assessed filings, 3 were flagged high-risk, 17 medium-risk, and 14 low-risk.
What are recent predictions and forward guidance from Vincerx Pharma, Inc.?
Forward guidance and predictions for Vincerx Pharma, Inc. are extracted from SEC filings as they are enriched.